That said, the lower proportion of patients with tumour shrinkage, short DoR, and the failure of the cohort to meet the prespecified rules that were required for the results to be considered positive argue for both a deeper understanding of ERBB2 oncogene addiction in this rare cancer and the need to focus on strategies such as combination therapy approaches with potential to enhance antitumour activity and improve outcomes. The gene discussed is ERBB2; the disease is neoplasm.